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Abstract
Background: Multiple Endocrine Neoplasia type 1 (MEN1) is diagnosed when two out of the three primary MEN1-
associated endocrine tumors occur in a patient. Up to 10–30 % of those patients have no mutation in the MEN1
gene. It is unclear if the phenotype and course of the disease of mutation-negative patients is comparable with
mutation-positive patients and if these patients have true MEN1. The present study aims to describe and compare
the clinical course of MEN1 mutation-negative patients with two out of the three main MEN1 manifestations and
mutation-positive patients during long-term follow-up.
Methods: This is a cohort study performed using the Dutch MEN1 database, including > 90 % of the Dutch MEN1
population.
Results: A total of 293 (90.7 %) mutation-positive and 30 (9.3 %) mutation-negative MEN1 patients were included.
Median age of developing the first main MEN1 manifestation was higher in mutation-negative patients (46 vs.
33 years) (P = 0.007). Mutation-negative patients did not develop a third main MEN1 manifestation in the course
of follow-up compared to 48.3 % of mutation-positive patients (P < 0.001). Median survival in mutation-positive
patients was estimated at 73.0 years (95 % CI, 69.5–76.5) compared to 87.0 years (95 % CI not available) in
mutation-negative patients (P = 0.001).
Conclusions: Mutation-positive and mutation-negative MEN1 patients have a different phenotype and clinical
course. Mutation-negative patients develop MEN1 manifestations at higher age and have a life expectancy comparable
with the general population. The apparent differences in clinical course suggest that MEN1 mutation-negative patients
do not have true MEN1, but another MEN1-like syndrome or sporadic co-incidence of two neuro-endocrine tumors.
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Background
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare
autosomal inherited disorder with an estimated preva-
lence of 1–10/100,000 and is characterized by the
occurrence of three primary manifestations: primary
hyperparathyroidism (pHPT), duodenopancreatic neuro-
endocrine tumors (dpNET) and pituitary tumors (PIT)
[1, 2]. According to the present clinical practice
guidelines [3], MEN1 is diagnosed based on clinical,
familial or genetic criteria. On the basis of clinical
criteria, MEN1 is diagnosed if at least two out of the
three primary MEN1 manifestations occur in a patient.
MEN1 is diagnosed on the basis of familial criteria if a
patient has a MEN1 manifestation in combination with
a first degree family member with MEN1. The identifica-
tion of a germline MEN1 mutation in an individual who
may be asymptomatic also confirms the diagnosis of
MEN1.
In 10–30 % of patients who were diagnosed with
MEN1 based upon clinical criteria, no mutation was
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found in the MEN1 gene [4–6]. These so called ‘pheno-
copies’ are an upcoming diagnostic challenge. With the
increased use and improvement of diagnostic tech-
niques, the incidence and prevalence of pHPT and micro
adenoma of the pituitary gland is rapidly rising. In a
population-based study [7], the prevalence of pHPT tri-
pled during the past two decades, increasing from 76
to 233 per 100,000 women and from 30 to 85 per
100,000 men. With an magnetic resonance imaging
(MRI) scan, which is now widely available, small pitu-
itary adenomas were found in as many as 10 % of
healthy volunteers [8]. These numbers implicate that
a large number of patients might strictly meet the
clinical criteria for MEN1 because of the co-incidence
of pHPT and pituitary adenoma. However, it is ques-
tionable whether those patients are at risk of develop-
ing other MEN1-associated tumors and will benefit
from intensive lifelong screening for MEN1-related
manifestations.
Recently, research concerning other genes has been
performed trying to explain the MEN1 clinical pheno-
type in cases of a mutation-negative MEN1 syndrome
[9, 10]. In a small series of patients, a small propor-
tion of the mutation-negative MEN1 patients ap-
peared to have a mutation in the CDKN1B gene [11].
These patients typically present with pituitary and
parathyroid tumors. The course of the disease ap-
peared also to be different in these patients for whom
the term MEN4 was introduced [12].
For MEN1 patients, once the syndrome is diagnosed,
the early detection of MEN1-associated tumors and sub-
sequent interventions seem to lead to a more favorable
course of the disease with a subsequent improved sur-
vival [13, 14]. Consequently, the current guidelines
advise an intensive follow-up of patients with frequent
laboratory and radiological investigations for all patients
irrespective of age [3]. It is, however, unclear if
mutation-negative patients are at risk for developing
further MEN1-related (neuro-)endocrine tumors and
benefit equally from this intensive follow-up as
mutation-positive patients do. To date, data on the
penetrance of clinical manifestations and survival of
MEN1 patients, irrespective their mutational status, are
based on single- or sometimes multi-institution studies of
mainly tertiary referral centers [15–20], which may have
led to a selection of patients included in the studies.
Therefore, the aim of the present study was to
compare the long-term clinical course of the disease
in MEN1 gene mutation-positive patients with MEN1
gene mutation-negative patients from the national
Dutch MEN1 cohort, including > 90 % of the MEN1
population. We studied incidence, age-related penetrance
of MEN1-related manifestations, and survival in both
groups of patients. Furthermore, the mutation-negative
patients were invited to undergo additional genetic testing,
including assessment of mutations in the CDKN1B gene.
Methods
Study design and patients
The study was performed using data from the Dutch
MEN1 study group database. This longitudinal database
includes > 90 % of all Dutch MEN1 patients, aged
16 years and older at the end of 2010, treated at one of
the Dutch University Medical Centers (UMCs) between
1990 and 2011 [21]. Data of all identified patients were
collected according to a predefined protocol, which was
based on predefined study questions from every quarter
of every available year of follow-up during the period
1990–2014. The study protocol was approved by the
Medical Ethical Committees of all UMCs in the
Netherlands. Given the retrospective and observational
data of the study, the use of these clinical data, including
the results of MEN1 gene testing, were approved for the
study aims and the requirement to obtain informed con-
sent was waived. For the additional genetic analyses of
CDKN1B and AIP genes in mutation-negative patients,
oral and written informed consent was obtained for the
testing and the use of the results in this study.
We assessed follow-up of patients with a known
MEN1 gene mutation (mutation-positive) and patients
with a negative MEN1 gene mutation test who had two
out of the three primary MEN1 manifestations (muta-
tion-negative).
Definitions of MEN1 manifestations
We defined pHPT as hypercalcemia combined with
elevated or inappropriately non-suppressed parathyroid
hormone levels in two consecutive measurements.
The reference test for the presence of pancreatic
neuroendocrine tumor (NET) was the outcome of
pathology examination. If pathology was not available,
pancreatic NET presence was based on MRI, computed
tomography (CT) or endoscopic ultrasound, which had
to be confirmed at least once by consecutive imaging
studies. The absence of pancreatic NET also had to be
confirmed on a minimum of two subsequent imaging
studies during follow-up [22]. A duodenal NET was
diagnosed with gastroduodenoscopy and, if available, by
pathology. A dpNET was diagnosed according to the
reference standard of pancreatic NET and duodenal
NET. Thymic-NET was diagnosed based upon the
results of pathology examination. Patients were consid-
ered to have a lung NET if (1) pathology examination
showed lung NET or (2) radiological examination was
positive for lung NET, as previously described [23].
Gastric NET was diagnosed by gastroduodenoscopy and
had to be confirmed by pathology.
de Laat et al. BMC Medicine  (2016) 14:182 Page 2 of 9
The reference standard for the presence of PIT was (1)
pathology or (2) radiological examination demonstrating
a PIT. Details for the reference standard of pit have been
described previously [24].
An adrenal tumor (ADR) was diagnosed based on
pathology, and if pathologic examination was not avail-
able, on radiological imaging (CT or MRI) which had to
be confirmed on subsequent imaging.
Genetic analysis
DNA was extracted from peripheral blood. The presence
of a MEN1 mutation was determined with DNA sequen-
cing since 1998 and with a combination of DNA sequen-
cing and multiplex ligation-dependent probe amplification
(MLPA) since 2005. MLPA (MRC-Holland, Amsterdam,
The Netherlands) is used for detecting large deletions or
duplications in the MEN1 gene. In addition, mutation-
negative patients were invited to participate in a genetic
screening program for familial NETs (including
CDKN1B and AIP). The presence of a CDKN1B and
AIP mutation was determined by direct sequencing.
In addition, MLPA was used for AIP to detect large
deletions or duplications. Sequences were analyzed
with Sequencing Analysis software version 5.2 (Ap-
plied Biosystems) and compared with the reference
sequences of each gene (Ensembl identifiers: MEN1
gene EST00000312049; CDKN1B gene: NM_004064.4
and AIP gene: ENST00000279146) using SeqScape
software version 2.5 (Applied Biosystems). Primer
sequences and PCR conditions are available on
request.
Outcome measures
The primary outcomes of the study were the age-related
penetrance of the MEN1 manifestations. The secondary
outcomes were the incidence of MEN1 manifestations
per 1000 patient-years and the survival of patients. The
primary and secondary outcomes were compared
between the mutation-positive and mutation-negative
patient groups.
Statistical analysis
Age-related penetrance of the primary MEN1 manifest-
ation and other MEN1-associated tumors was estimated
using the Kaplan–Meier method. Age-related penetrance
was calculated for the age per manifestation, and for the
age on which a first, second, and third major MEN1
manifestation was diagnosed.
Subgroup analyses for mutation-positive and mutation-
negative patients was performed for the age of first,
second, and third major MEN1 manifestation and the
occurrence of the first other MEN1-associated tumor. In
addition, a subgroup analyses was performed comparing
patients in whom MEN1 was diagnosed because of the
occurrence of two of the primary MEN1 manifestations
(index patients) who were mutation-positive on the one
hand and mutation-negative patients on the other. Index
patients were not siblings of a known MEN1 family before
clinical diagnosis of MEN1 and testing. Comparison of
Kaplan–Meier curves was made using the Log-rank test.
Survival was compared for mutation-positive and
mutation-negative patients using the Kaplan–Meier
method. Cause of death was subdivided in MEN1 related
and non-MEN1 related. Comparison was made using
the Log-rank test. Cause and age of death was compared
between mutation-positive and mutation-negative
patients.
Incidence rate was calculated for the three primary
MEN1 manifestations. For calculation of incidence, only
tumors detected at follow-up of patients with MEN1
syndrome, i.e. after establishing the MEN1 diagnosis,
were considered.
To describe clinical characteristics, the mean ± SD or
median with range was calculated, depending on the
normal distribution. Continuous variables were analyzed
by using independent sample t-test or Mann–Whitney U
test. Dichotomous variables were compared with Fisher
exact test or χ2 test.
Statistical significance was set at P < 0.05 and the ana-
lyses were conducted using SPSS 20.0.
Results
Study population
In the period 1990–2011, a total of 322 MEN1 patients
were included in the database. There was a female pre-
dominance (n = 187, 58.1 %) and the patients were part
of 121 different MEN1 families. At the moment of
genetic testing, 100 patients were diagnosed based on
clinical grounds and those patients were not siblings of a
known MEN1 family. These patients represent the
subgroup of index patients, 70 (70 %) of whom tested
positive and 30 (30 %) tested negative for the MEN1
mutation. The other patients were all mutation-positive
siblings of already known MEN1 families; 91 were
pre-symptomatic at testing, and 131 patients were tested
after development of the first MEN1 manifestation. The
total number of MEN1-positive patients was 292
(90.7 %).
The median age of diagnosis of MEN1 was 37 years
(range 8–78). In MEN1 gene mutation-negative patients,
median age of diagnosis of MEN1 was 55 years (range
23–78), and was 20 years higher than the age of diagno-
sis of mutation-positive MEN1 patients (median age
MEN1 diagnosis 35 years (range 8–78 years); P < 0.001).
Clinical manifestations
In 92 % of the patients, at least one of the three main
MEN1 manifestations was diagnosed. pHPT occurred in
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87.0 % of patients and was diagnosed at a mean age
of 36 years (SD 14 years). The youngest patient diag-
nosed with pHPT was 11 years old. dpNET occurred
in 55.9 % and PIT in 43.8 %. The mean age at diag-
nosis of dpNET and PIT was 41 years (SD 15 years)
and 40 years (SD 15 years), respectively. Age-related
penetrance for the three main manifestations is pre-
sented in Fig. 1a–c. The prevalence of other manifes-
tations associated with MEN1 was gastric NET in 3.7 %,
lung NET in 19.3 %, thymic NET in 4.0 %, and ADR in
31.4 % of patients (Table 1). Median age and range
for all manifestations are presented in Additional file 1:
Table S1.
Incidence of primary MEN1 manifestations
Primary hyperparathyroidism was predominantly diag-
nosed before MEN1 was diagnosed. Therefore, the
incidence of pHPT during follow-up was ‘only’ 144.5
per 1000 patient-years (95 % confidence interval (CI),
113.3–181.8; 73 new cases in 119 patients followed
505 patient-years). Incidence of PIT was 39.6 per
1000 patient-years (95 % CI, 31.7–48.9; 87 new cases
in 230 patients followed 2195 patient-years). The inci-
dence of dpNET was 62.3 per 1000 patient-years
(95 % CI, 51.8–74.3; 124 new cases in 241 patients
followed for 1990 patient-years.
Age-related penetrance
The median age at which patients developed the first
major manifestation was 13 years higher in MEN1
mutation-negative patients: 46.0 years (95 % CI, 39.6–
52.4) compared to 33.0 years (95 % CI, 30.9–35.1) in
MEN1 mutation-positive patients (P = 0.007) (Fig. 2a).
Median age at developing the second major manifest-
ation was 9 years higher in mutation-negative patients;
however, the difference was not significant, 55.0 years
(95 % CI, 48.3–61.7) in MEN1 mutation-negative
patients versus 46.0 years (95 % CI, 43.3–48.7) in
mutation-positive patients (P = 0.559) (Fig. 2b). A
third main manifestation did not develop in MEN1
mutation-negative patients, compared to a total of 76
in the mutation-positive patient group, corresponding
with a median age of 72 for developing the third
manifestation (P < 0.001) (Fig. 2c). Finally, other MEN1-
associated manifestations developed in only one pa-
tient who was MEN1 mutation-negative (ADR), while
48.3 % of mutation-positive patients developed such
manifestations at a median age of 57.0 (53.5–60.5)
(Fig. 2d).
Comparable results were found when the subgroup
of index patients and mutation-negative patients were
compared (Additional file 1: Figure S1). In this sub-
group analysis, the mean age at diagnosis of the sec-
ond major manifestation in mutation-positive index
cases was 38.0 years (95 % CI, 35.8–40.2), which is
17 years younger compared to mutation-negative pa-
tients (P = 0.003). A third main manifestation was
found in 32 mutation-positive index cases at a median
age of 65 years.
Survival
After a median follow-up period from the moment of
MEN1 diagnosis of 10 years (range 0–47 years), 54 pa-
tients died (16.8 %). Cause of death can be found in
Additional file 1: Table S2. Among the mutation-positive
MEN1 patients, 51 died (17.5 %), of whom 30 (58.8 %)
due to a MEN1-related cause. The mean age of death
was 60 years (SD 12 years). Among mutation-negative
patients, three patients died (10.0 %) from causes not
related to MEN1. Survival curves are presented in
Additional file 1 (Fig. 3). Median survival in mutation-
positive patients was estimated at 73.0 years (95 % CI,
69.5–76.5) compared to 87.0 years (95 % CI not avail-
able) in mutation-negative patients (P = 0.001).
Fig. 1 Age-related penetrance of the main MEN1 manifestations. a Age-related penetrance of duodenopancreatic neuroendocrine tumors.
b Age-related penetrance of pituitary tumors. c Age-related penetrance of primary hyperparathyroidism
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Survival in mutation-positive index patients was
comparable with the survival in other mutation-
positive cases. Median survival in mutation-positive
index cases was estimated at 72.0 years (95 % CI,
67.0–77.0; Additional file 1: Figure S2). A total of 22
mutation-positive index patients died during follow-up,
16 (72.7 %) of whom due to a MEN1-related cause
(Additional file 1: Table S4).
Additional genetic results in mutation-negative patients
Full results of manifestation and additional genetic testing in
MEN1 mutation-negative patients are summarized in Add-
itional file 1: Table S3. In the 30 mutation-negative patients,
no family members with MEN1 were identified. A pHPT/PIT
phenotype was present in 23 patients (76.7 %), five patients
had pHPT/dpNET (16.7 %) and two had PIT/dpNET (6.7 %).
In 21 of 27 patients (77.8 %) who were still alive,
permission was obtained for additional genetic ana-
lysis, one patient could not give permission because
of the presence of dementia. In all 21 patients, gen-
etic testing for CDKN1B had been performed, which
revealed a CDKN1B mutation in one patient. This
patient, who was diagnosed with pHPT and PIT, had
a mutation in the CDKN1B gene (c.295_305dup
p.Gln104Argfs*19). At this location a duplication of
11 base pairs was detected in exon 1, causing a frame
shift starting at codon Gln104. The new reading
frame ends in a STOP codon 18 positions downstream. In
Table 1 Prevalence of MEN1 manifestations
MEN1 manifestations Total Mutation-
positive
Mutation-
negative
n (%) n (%) n (%)
Number of patients 322 292 30
Primary hyperparathyroidism 280 (87.0) 252 (86.0) 28 (93.3)
Duodenopancreatic
neuroendocrine tumors
180 (55.9) 173 (59.2) 7 (23.3)
Pituitary tumor 141 (49.6) 116 (39.7) 25 (83.3)
Lung neuroendocrine tumor 62 (19.3) 62 (21.2) 0
Thymic neuroendocrine tumor 13 (4.0) 13 (4.5) 0
Gastric neuroendocrine tumor 12 (3.7) 12 (4.1) 0
Adrenal tumor 101 (31.4) 100 (34.1) 1 (3.3)
Fig. 2 Age-related penetrance of major manifestations and other MEN1-associated tumors compared between mutation-positive patients and
mutation-negative patients. a Age-related penetrance of the first manifestation (Log-rank test P = 0.007). b Age-related penetrance of the second
manifestation (Log-rank test P = 0.559). c Age-related penetrance of the third manifestation (Log-rank test P < 0.001). d Age-related penetrance of
other MEN1-associated neuroendocrine tumors (Log-rank test P = 0.003)
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19 out of 21 patients, genetic testing for AIP was
performed, which did not result in additional mutations.
Discussion
In the Netherlands, MEN1 patients have an increased risk
of premature death with an estimated median survival of
73 years, which is almost 10 years shorter compared with
the general Dutch population. MEN1 mutation-negative
patients appeared to have a far less aggressive course of dis-
ease. In mutation-negative patients, the age of the first
MEN1 manifestation was higher, and a third MEN1-related
manifestation hardly ever occurred. A striking result is the
difference in age of death and median survival whenMEN1
mutation-positive patients are compared with mutation-
negative patients. The shorter life expectancy of mutation-
positive MEN1 patients is in line with previous literature.
The apparent differences in penetrance of MEN1 manifes-
tations and survival between MEN1 mutation-negative and
positive patients indicate that MEN1 mutation-negative
patients with two out of the three main MEN1 manifesta-
tions have a different MEN1 mimicking disease. Additional
testing for CDKN1B mutations in our national MEN1
cohort led to one positive, not previously described,
mutation underlining the rarity of CDKN1B mutations as
explanation for the MEN1 phenotype.
Strengths
To minimize selection bias, age-related penetrance was
analyzed in the national Dutch MEN1 study group co-
hort of MEN1 patients, which includes more than 90 %
of the total Dutch MEN1 population [21]. The follow-up
data was collected based on pre-defined study questions
and according to a standardized protocol for every
quarter of every year from 1990 up to 2011. The data-
base is considered of high quality for its high density of
reliable data and long-term follow-up. To our knowledge
for the first time, the age-related penetrance and age of
death were compared between mutation-positive and
mutation-negative patients. Diagnosis of a MEN1 mani-
festation was established through predefined reference
standards to increase reliability. MEN1 manifestations di-
agnosed only on imaging had to be confirmed on con-
secutive examinations leading to a valid diagnosis. Further,
assessment of the incidence of newly diagnosed manifesta-
tions over time is relatively new in the MEN1 research
field. In this study, additional testing for mutations in the
CDKN1B gene was performed and the finding of only one
positive test underlines the rarity of these mutations when
also tested in a national cohort.
Comparison with the other literature
The prevalence of the major MEN1-related manifesta-
tions, age-related penetrance and the survival rates are
comparable with the present literature [19, 20, 25]. The
previously reported percentages of mutation-negative
patients vary, but our 9.3 % compares low to some earl-
ier studies [3, 5, 6]. Moreover, in previous studies, more
than 50 % of index patients without a family history of
MEN1 were mutation-negative, compared to 30 % in
our study [6, 26–28]. The mutation-negative patients in-
cluded in our database generally underwent the recently
implemented MLPA analysis, which increased the sensi-
tivity of MEN1 gene analysis leading to a lower propor-
tion of MEN1 mutation-negative patients. In another
recent study, a comparable rate of 10 % mutation-
negative patients was identified [4].
Previous studies have reported that mutation-negative
patients are predominantly index patients without a fam-
ily history of MEN1 [6, 26–28]. In our cohort all
mutation-negative patients were index patients, confirm-
ing the results of previous reports. In some reports it
was already suggested that patients scoring negative on
both mutational testing and familial history more often
have mild clinical presentation [26, 28]. We have now
demonstrated that the differences in the clinical course
of mutation-positive and negative patients are lasting at
long-term follow-up. Index patients who scored positive at
mutational testing, however, have a comparable course of
the disease as patients with familial occurrence of MEN1.
The differences in clinical course suggest that the mutation-
negative patients may not have the MEN1 syndrome.
Recently, a new germ-line mutation in the CDKN1B
gene [11] was discovered in mutation-negative MEN1
patients, which is now identified as MEN4. Incidence
and clinical implications of MEN4 syndrome are still un-
known [12]. Mutations of the MEN1 gene and CDKN1B
polymorphisms can also coincide, resulting in early
Fig. 3 Survival curve of MEN1 patients, comparing between
mutation-positive and mutation-negative patients
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development of aggressive tumors in MEN1 patients
[29]. In our cohort, permission for additional genetic
analysis was obtained from 21 of 27 live patients
(77.8 %). Only one CDKN1B mutation was found in all
tested patients. Our findings are in accordance with the
few studies published in which sporadic and familial
cases of mutation-negative MEN1 patients are tested for
CDKN1B [5, 30–33]. These studies also show that muta-
tions in CDKN1B and the other genes coding CDKIs are
extremely rare, and many patients who are mutation-
negative and have a MEN1 like disease still have a genet-
ically unexplained phenotype.
The CDKN1B mutation, which we found in one
patient, had not been described before. The duplication
of 11 base pairs causes a frame shift, resulting in a STOP
codon. The mRNA produced might be targeted for non-
sense mediated decay. We assume that this is a patho-
genic mutation, because of the presence of an STOP
codon. A number of somatic mutations in exon 1 of the
CDKN1B gene are described.
Strictly spoken, we might have missed mutation-
negative patients with two main MEN1-associated tu-
mors who were not referred to one of the UMCs.
However, in the Dutch healthcare system, especially
patients with a lower age of diagnosis of manifesta-
tions or a more aggressive course of the disease are
generally referred to one of the UMCs. Missing
patients who were not referred can therefore be
expected to have led to an underestimation of the dif-
ferences between the MEN1 mutation-positive and
-negative patients underlining the validity of the re-
sults. Finally, in The Netherlands, all genetic tests for
MEN1 are performed only at the genetic laboratory
of the UMC Utrecht, leading to completeness of the
data. Extrapolating the clinical data from the applica-
tion forms for the genetic tests that led to negative
results led to the conclusion that the majority of
mutation-negative patients had been included [21].
Limitations
Nine of the 30 mutation-negative patients were not
tested for CDKN1B. These missing data could lead to an
underestimation of the incidence of CDKN1B mutations
among the MEN1 mutation-negative patients. However,
the low prevalence of CDKN1B mutations is in line with
previous literature.
At the moment of diagnosis of the first manifestation,
the MEN1 mutation-negative patients were not sus-
pected to have MEN1 by the treating physician. There-
fore, routine follow-up and screening as part of the
MEN1 protocol started only after diagnosis of the
second main manifestation. Thus, age of the second
manifestation might be overestimated in the mutation-
negative patients. However, the outcomes were
confirmed by the results of the additional analysis in
which MEN1 mutation-negative patients were compared
with newly diagnosed MEN1 mutation-positive patients
(index patients) who often underwent mutation analyses
because of the combination of two MEN1 manifestations
and also started structured follow-up after the diagnosis
of MEN1.
Clinical implications
According to our results, the age of MEN1 diagnosis
and the age of the MEN1 manifestations are significantly
higher in mutation-negative patients with two of the
main MEN1-associated tumors. We have now demon-
strated that these patients also have a more favorable
clinical course, justifying the concept that these patients
might not have a true MEN1 syndrome, but a MEN1-
like syndrome or sporadic co-incidence of two (neuroen-
docrine) tumors. According to the favorable clinical
course of these patients, it is questionable whether or
not these patients should be intensively screened for fu-
ture endocrine events according to the clinical guidelines
for MEN1 patients.
Caution is warranted when encountering a
mutation-negative patient who has a positive family
history for MEN1 or with three MEN1-related mani-
festations. In our cohort, all mutation-negative pa-
tients were index cases with two main MEN1-related
manifestations and a negative family history; how-
ever, previous papers have reported negative muta-
tional testing in patients with familial occurring
MEN1 [6, 26, 28]. We do expect that cases with a
negative mutational testing in combination with a
positive family history will become highly uncom-
mon in the present era of highly sensitive tests such
as MLPA and next generation sequencing [34, 35].
Conclusions
In conclusion, MEN1 is a syndrome with high life-time
occurrence of pHPT, dpNET, and PIT and a considerable
risk of premature death with an estimated median
survival of 73 years. MEN1 mutation-positive and
mutation-negative patients have a different clinical
course, with mutation-negative patients developing
MEN1 manifestations at a higher age and having a me-
dian survival comparable to the general population,
which is 10 years longer than MEN1 mutation-positive
patients. Mutations in the CDKN1B gene can be consid-
ered a rarity and do not fully explain the occurrence of
MEN1 phenocopies. The apparent differences in clinical
course suggests that mutation-negative patients with two
out of the three main MEN1 manifestations do not have
true MEN1, but another MEN1-like syndrome or
sporadic co- incidence of two NETs.
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Additional file 1: Table S1. Age of diagnosis of MEN1-associated
manifestations. Table S2. Causes of mortality. Table S3. Clinical
characteristics and results of genetic screening. Figure S1. Age-related
penetrance of major manifestations and other MEN1-associated tumors
compared between mutation positive index patients and mutation negative
patients. Figure S2. Survival curve of MEN1 patients, comparing between
mutation-positive and mutation-negative index patients. Table S4. Causes
of mortality in index cases. (PDF 928 kb)
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